Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-25-065546
Filing Date
2025-03-27
Accepted
2025-03-27 16:30:34
Documents
9
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K d888799d10k.htm 10-K 1157355
2 EX-4.5 d888799dex45.htm EX-4.5 152279
3 EX-19 d888799dex19.htm EX-19 46561
4 EX-21 d888799dex21.htm EX-21 704
5 EX-31.1 d888799dex311.htm EX-31.1 6907
6 EX-31.2 d888799dex312.htm EX-31.2 6968
7 EX-32.1 d888799dex321.htm EX-32.1 3702
8 EX-32.2 d888799dex322.htm EX-32.2 3768
9 EX-97 d888799dex97.htm EX-97 21951
  Complete submission text file 0001193125-25-065546.txt   1401263
Mailing Address 333 SOUTH GRAND AVENUE, 28TH FLOOR LOS ANGELES CA 90071
Business Address 333 SOUTH GRAND AVENUE, 28TH FLOOR LOS ANGELES CA 90071 213-830-6300
Oaktree Acquisition Corp. III Life Sciences (Filer) CIK: 0002029769 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-42383 | Film No.: 25779865
SIC: 6770 Blank Checks
(CF Office: 05 Real Estate & Construction)